vs
NAVIENT CORP（NAVI）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是NAVIENT CORP的1.4倍（$197.9M vs $137.0M），REPLIGEN CORP净利率更高（6.7% vs -5.0%，领先11.8%），REPLIGEN CORP同比增速更快（13.6% vs -38.3%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -30.9%）
纳文特公司是一家总部位于美国特拉华州威尔明顿的金融服务企业，前身是学生贷款服务商。公司于2014年由学生贷款机构萨利美拆分而来，目前在美国各地设有办事处，共有约4500名员工，2018年时曾承接全美四分之一的学生贷款业务，2024年被禁止承接联邦学生贷款业务。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
NAVI vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.4倍
$137.0M
营收增速更快
RGEN
高出51.9%
-38.3%
净利率更高
RGEN
高出11.8%
-5.0%
两年增速更快
RGEN
近两年复合增速
-30.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $137.0M | $197.9M |
| 净利润 | $-6.0M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -5.9% | 9.0% |
| 净利率 | -5.0% | 6.7% |
| 营收同比 | -38.3% | 13.6% |
| 净利润同比 | -125.0% | 143.9% |
| 每股收益（稀释后） | $-0.05 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NAVIRGEN
| Q4 25 | $137.0M | $197.9M | ||
| Q3 25 | $161.0M | $188.8M | ||
| Q2 25 | $156.0M | $182.4M | ||
| Q1 25 | $156.0M | $169.2M | ||
| Q4 24 | $222.0M | $174.1M | ||
| Q3 24 | $396.0M | $154.9M | ||
| Q2 24 | $247.0M | $154.1M | ||
| Q1 24 | $287.0M | $151.3M |
净利润NAVIRGEN
| Q4 25 | $-6.0M | $13.3M | ||
| Q3 25 | $-86.0M | $14.9M | ||
| Q2 25 | $14.0M | $14.9M | ||
| Q1 25 | $-2.0M | $5.8M | ||
| Q4 24 | $24.0M | $-30.3M | ||
| Q3 24 | $-2.0M | $-654.0K | ||
| Q2 24 | $36.0M | $3.3M | ||
| Q1 24 | $73.0M | $2.1M |
毛利率NAVIRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率NAVIRGEN
| Q4 25 | -5.9% | 9.0% | ||
| Q3 25 | -72.7% | 8.9% | ||
| Q2 25 | 11.5% | 7.6% | ||
| Q1 25 | -3.2% | 3.9% | ||
| Q4 24 | 11.7% | -17.7% | ||
| Q3 24 | 3.0% | -5.1% | ||
| Q2 24 | 19.4% | 1.0% | ||
| Q1 24 | 30.7% | 1.3% |
净利率NAVIRGEN
| Q4 25 | -5.0% | 6.7% | ||
| Q3 25 | -53.4% | 7.9% | ||
| Q2 25 | 9.0% | 8.2% | ||
| Q1 25 | -1.3% | 3.4% | ||
| Q4 24 | 10.8% | -17.4% | ||
| Q3 24 | -0.5% | -0.4% | ||
| Q2 24 | 14.6% | 2.2% | ||
| Q1 24 | 25.4% | 1.4% |
每股收益（稀释后）NAVIRGEN
| Q4 25 | $-0.05 | $0.24 | ||
| Q3 25 | $-0.87 | $0.26 | ||
| Q2 25 | $0.13 | $0.26 | ||
| Q1 25 | $-0.02 | $0.10 | ||
| Q4 24 | $0.24 | $-0.55 | ||
| Q3 24 | $-0.02 | $-0.01 | ||
| Q2 24 | $0.32 | $0.06 | ||
| Q1 24 | $0.64 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $637.0M | $767.6M |
| 总债务越低越好 | $40.6B | $542.2M |
| 股东权益账面价值 | $2.4B | $2.1B |
| 总资产 | $48.7B | $2.9B |
| 负债/权益比越低杠杆越低 | 16.94× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资NAVIRGEN
| Q4 25 | $637.0M | $767.6M | ||
| Q3 25 | $571.0M | $748.7M | ||
| Q2 25 | $712.0M | $708.9M | ||
| Q1 25 | $642.0M | $697.2M | ||
| Q4 24 | $722.0M | $757.4M | ||
| Q3 24 | $1.1B | $784.0M | ||
| Q2 24 | $1.1B | $809.1M | ||
| Q1 24 | $823.0M | $780.6M |
总债务NAVIRGEN
| Q4 25 | $40.6B | $542.2M | ||
| Q3 25 | $41.4B | $537.9M | ||
| Q2 25 | $42.3B | — | ||
| Q1 25 | $42.9B | — | ||
| Q4 24 | $43.2B | $525.6M | ||
| Q3 24 | $44.7B | — | ||
| Q2 24 | $47.5B | — | ||
| Q1 24 | $50.8B | — |
股东权益NAVIRGEN
| Q4 25 | $2.4B | $2.1B | ||
| Q3 25 | $2.4B | $2.1B | ||
| Q2 25 | $2.6B | $2.1B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.6B | $2.0B | ||
| Q3 24 | $2.7B | $2.0B | ||
| Q2 24 | $2.7B | $2.0B | ||
| Q1 24 | $2.8B | $2.0B |
总资产NAVIRGEN
| Q4 25 | $48.7B | $2.9B | ||
| Q3 25 | $49.3B | $2.9B | ||
| Q2 25 | $50.2B | $2.9B | ||
| Q1 25 | $51.0B | $2.9B | ||
| Q4 24 | $51.8B | $2.8B | ||
| Q3 24 | $53.4B | $2.8B | ||
| Q2 24 | $56.6B | $2.9B | ||
| Q1 24 | $59.0B | $2.8B |
负债/权益比NAVIRGEN
| Q4 25 | 16.94× | 0.26× | ||
| Q3 25 | 16.98× | 0.26× | ||
| Q2 25 | 16.52× | — | ||
| Q1 25 | 16.56× | — | ||
| Q4 24 | 16.35× | 0.27× | ||
| Q3 24 | 16.59× | — | ||
| Q2 24 | 17.30× | — | ||
| Q1 24 | 18.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $441.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流NAVIRGEN
| Q4 25 | $441.0M | $25.7M | ||
| Q3 25 | $70.0M | $48.1M | ||
| Q2 25 | $126.0M | $28.6M | ||
| Q1 25 | $71.0M | $15.0M | ||
| Q4 24 | $459.0M | $39.2M | ||
| Q3 24 | $-10.0M | $49.3M | ||
| Q2 24 | $279.0M | $42.2M | ||
| Q1 24 | $182.0M | $44.7M |
自由现金流NAVIRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M | ||
| Q1 24 | — | $36.4M |
自由现金流率NAVIRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% | ||
| Q1 24 | — | 24.0% |
资本支出强度NAVIRGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 5.5% |
现金转化率NAVIRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | 9.00× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | 19.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 7.75× | 12.70× | ||
| Q1 24 | 2.49× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
